Detalles de la búsqueda
1.
Trial of Solanezumab in Preclinical Alzheimer's Disease.
N Engl J Med
; 389(12): 1096-1107, 2023 Sep 21.
Artículo
Inglés
| MEDLINE | ID: mdl-37458272
2.
Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease.
Ann Neurol
; 92(5): 729-744, 2022 11.
Artículo
Inglés
| MEDLINE | ID: mdl-36151869
3.
Targeting amyloid ß in Alzheimer's disease: Meta-analysis of low-dose solanezumab in Alzheimer's disease with mild dementia studies.
Alzheimers Dement
; 19(10): 4619-4628, 2023 10.
Artículo
Inglés
| MEDLINE | ID: mdl-36946603
4.
Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial.
JAMA Neurol
; 2024 Apr 29.
Artículo
Inglés
| MEDLINE | ID: mdl-38683602
5.
Validation and diagnostic accuracy of the Alzheimer's questionnaire.
Age Ageing
; 41(3): 396-9, 2012 May.
Artículo
Inglés
| MEDLINE | ID: mdl-22367356
6.
Magnetic resonance imaging measures of brain volumes across the EXPEDITION trials in mild and moderate Alzheimer's disease dementia.
Alzheimers Dement (N Y)
; 8(1): e12313, 2022.
Artículo
Inglés
| MEDLINE | ID: mdl-35783453
7.
Avoid or Embrace? Practice Effects in Alzheimer's Disease Prevention Trials.
Front Aging Neurosci
; 14: 883131, 2022.
Artículo
Inglés
| MEDLINE | ID: mdl-35783127
8.
Evaluation of dose-dependent treatment effects after mid-trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease.
Alzheimers Dement (Amst)
; 14(1): e12367, 2022.
Artículo
Inglés
| MEDLINE | ID: mdl-36348972
9.
Brain amyloid burden, sleep, and 24-hour rest/activity rhythms: screening findings from the Anti-Amyloid Treatment in Asymptomatic Alzheimer's and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration Studies.
Sleep Adv
; 2(1): zpab015, 2021.
Artículo
Inglés
| MEDLINE | ID: mdl-34661109
10.
Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals.
JAMA Neurol
; 77(6): 735-745, 2020 06 01.
Artículo
Inglés
| MEDLINE | ID: mdl-32250387
11.
Medical management of frontotemporal dementia.
Am J Alzheimers Dis Other Demen
; 22(6): 489-98, 2007.
Artículo
Inglés
| MEDLINE | ID: mdl-18166608
12.
Utility of the telephone interview for cognitive status for enrollment in clinical trials.
Alzheimers Dement
; 2(2): 104-9, 2006 Apr.
Artículo
Inglés
| MEDLINE | ID: mdl-19595866
13.
Density of the brain, decline of the mind: an atypical case of Fahr disease.
Arch Neurol
; 64(5): 756-7, 2007 May.
Artículo
Inglés
| MEDLINE | ID: mdl-17502478
14.
Pilot randomized controlled study of a histamine receptor inverse agonist in the symptomatic treatment of AD.
Curr Alzheimer Res
; 9(4): 481-90, 2012 May.
Artículo
Inglés
| MEDLINE | ID: mdl-22272611
15.
Reversible dementia and gait disturbance after prolonged use of valproic acid.
Seizure
; 20(6): 509-11, 2011 Jul.
Artículo
Inglés
| MEDLINE | ID: mdl-21435910
16.
The Alzheimer's questionnaire: a proof of concept study for a new informant-based dementia assessment.
J Alzheimers Dis
; 22(3): 1015-21, 2010.
Artículo
Inglés
| MEDLINE | ID: mdl-20930293
17.
Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the APOE ε4 allele, the major late-onset Alzheimer's susceptibility gene.
J Alzheimers Dis
; 22(1): 307-13, 2010.
Artículo
Inglés
| MEDLINE | ID: mdl-20847408
18.
Out of sight, out of mind: the case of a 62-year-old man with visual complaints and cognitive decline.
Prim Care Companion CNS Disord
; 16(1)2014.
Artículo
Inglés
| MEDLINE | ID: mdl-24940515
19.
Non-cholinergic drug development for Alzheimer's disease.
Expert Opin Drug Discov
; 3(7): 745-60, 2008 Jul.
Artículo
Inglés
| MEDLINE | ID: mdl-23496218
20.
Preserving independence: treatment decisions over 4 years in an elderly woman with cognitive decline.
Prim Care Companion CNS Disord
; 15(4)2013.
Artículo
Inglés
| MEDLINE | ID: mdl-24392253